Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?

Amber Fullmer; Elias Jabbour

doi:10.1002/ajh.21649

Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?

Amber Fullmer, Elias Jabbour

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	158-159
Number of pages	2
Journal	American journal of hematology
Volume	85
Issue number	3
DOIs	https://doi.org/10.1002/ajh.21649
State	Published - Mar 2010

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.21649

Cite this

@article{652b3861faa74d9db193a3447ea78166,

title = "Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?",

author = "Amber Fullmer and Elias Jabbour",

year = "2010",

month = mar,

doi = "10.1002/ajh.21649",

language = "English (US)",

volume = "85",

pages = "158--159",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors

T2 - What is the optimal regimen?

AU - Fullmer, Amber

AU - Jabbour, Elias

PY - 2010/3

Y1 - 2010/3

UR - http://www.scopus.com/inward/record.url?scp=77249104570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249104570&partnerID=8YFLogxK

U2 - 10.1002/ajh.21649

DO - 10.1002/ajh.21649

M3 - Comment/debate

C2 - 20131307

AN - SCOPUS:77249104570

SN - 0361-8609

VL - 85

SP - 158

EP - 159

JO - American journal of hematology

JF - American journal of hematology

IS - 3

ER -

Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this